Rod cGMP-specific 3',5'-phosphodiesterase subunit alpha (PDE6A)

Rod cGMP-specific 3',5'-phosphodiesterase subunit alpha (PDE6A) is a critical enzyme located in the outer segments of rod photoreceptor cells in the retina. It serves as the central effector of the vertebrate phototransduction cascade, where it is activated by the G-protein transducin following light stimulation. Once activated, the PDE6 holoenzyme rapidly hydrolyzes cyclic GMP (cGMP), leading to the closure of cGMP-gated cation channels, cell hyperpolarization, and the transmission of visual signals to the brain (UniProt P16499; PMC7566066). Mutations in the PDE6A gene are a known cause of autosomal recessive retinitis pigmentosa (RP43), a condition characterized by the progressive degeneration of rod and cone photoreceptors (PubMed 40825661). Therapeutically, PDE6A is a primary target for emerging gene supplementation therapies, such as rAAV8.hPDE6A, which aim to restore enzyme function and prevent blindness (ClinicalTrials.gov NCT04611503). However, recent clinical trials have highlighted challenges, including potential retinal thinning and lack of significant visual improvement in advanced disease stages (PubMed 40825661). Additionally, PDE6A is a notable off-target for PDE5 inhibitors like sildenafil and vardenafil, which can cause transient visual disturbances due to cross-reactivity with the retinal enzyme (PMC3422662). Understanding its structural and regulatory mechanisms remains vital for developing both curative genetic treatments and more selective pharmacological agents.

Other names

PDE6 alphaPhosphodiesterase 6AGMP-PDE alphaPDEARP43

Hydrolysis of cyclic GMP (cGMP) to 5'-GMP in rod photoreceptors, which regulates the closure of cGMP-gated cation channels and leads to cell hyperpolarization in response to light.